Intelligent Bio Solutions announces new data on IFDDS

Intelligent Bio Solutions (INBS) announced the successful collection of new data that further reinforces the security and performance of its Intelligent Fingerprinting Drug Screening System, IFDDS, strengthening its FDA 510(k) submission. “Our ongoing dialogue with the FDA throughout the 510(k) process has been constructive and forward-looking,” said Peter Passaris, Vice President of Product Development. “With the support of specialized FDA consultants and expert third-party partners, our team has worked diligently to address each question thoroughly. We are planning to submit our findings to the FDA in August, along with the new data collected.”